Three biotechs set terms in a hunt for $475M-plus; Leap Therapeutics earns a trial win across DKK1 high expressing tumors
We have a slate of biotech IPO terms to report this morning.
Design Therapeutics is applying a high valuation to the company. The preclinical biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
